Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy

19 Jan 2026 CW Team

The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio.

The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary.

This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026.

The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets.

Net proceeds will be utilised towards:

Payment to Viatris for acquisition of Biocon Biologics shares

Repayment of debt linked to the acquisition

Funding for redemption of compulsorily convertible debentures held by Biocon Biologics

General corporate purposes

The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025.

Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4.15 billion (approximately USD 460 million) through the issuance of 12,664,585 equity shares at an issue price of Rs 368.35 per share, including a premium of Rs 363.35. The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio. The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary. This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026. The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets. Net proceeds will be utilised towards: Payment to Viatris for acquisition of Biocon Biologics shares Repayment of debt linked to the acquisition Funding for redemption of compulsorily convertible debentures held by Biocon Biologics General corporate purposes The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025. Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Real Estate

28 Feb 2026

Casagrand Launches Keystone In Tiruppur

Casagrand has launched Casagrand Keystone, a gated residential development at Rakkiyapalayam, off Avinashi Road, in Tiruppur. Spread across 2.2 acres, the B+G+5 structure comprises 142 units of 2 and 3 BHK homes, supported by 48 indoor and outdoor amenities. The project is introduced at a starting price of Rs 5,199 per sq. ft. The development allocates 1.3 acres to open space, including a central park of about 24,500 sq. ft. A 6,800 sq. ft. clubhouse includes a multipurpose hall, mini theatre and indoor recreation facilities. Other amenities include a 5,100 sq. ft. swimming pool, poolside par..

Real Estate

28 Feb 2026

Premium homes account for half of India’s housing sales in 2025

Knight Frank India, in its latest report on India’s office and residential property market, has highlighted a significant shift in housing demand, with homes priced above Rs 10 million accounting for 50 per cent of total residential sales across the top eight cities in 2025. The findings underscore the growing dominance of premium housing in the country’s real estate landscape.Out of 348,247 residential units sold during the year, approximately 175,091 units were in the Rs 10 million-plus category, marking a 14 per cent year-on-year increase. The data reflects changing buyer preferences, w..

Infrastructure Energy

28 Feb 2026

Xbattery launches XB-5K energy storage system for homes, offices

Xbattery, a Hyderabad-based deep-tech company specialising in next-generation energy storage and battery management technologies, has introduced its flagship XB-5K, a scalable 5kWh energy storage system designed for homes and offices in India.The XB-5K is built on the company’s indigenously developed BharatBMS platform, described as India’s first universal high-voltage battery management system architecture aimed at reducing import dependence and improving after-sales service capabilities. The launch comes as India seeks to strengthen domestic manufacturing and address reliance on imported..